X
Bayer files prostate cancer drug darolutamide in Japan
https://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
Astellas
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications
Jo Taylor moves to Cello Health Communications
UK’s KaNDy Therapeutics funds mid-stage trial of HRT ‘replacement’
Biotech hopes for IPO or big pharma deal to fund phase 3
Seattle Genetics and Astellas gain Breakthrough Designation for urothelial cancer treatment
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
1 2
